STOCK TITAN

Context Therapeutics Inc - CNTX STOCK NEWS

Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.

Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company pioneering T cell-engaging bispecific antibody therapies for solid tumors. This page serves as the definitive source for verified news and official updates about the company's innovative oncology pipeline, including clinical trial progress, regulatory milestones, and strategic partnerships.

Investors and researchers will find curated updates on key programs like CTIM-76 (targeting CLDN6+ cancers) and CT-95/CT-202 bispecific antibodies. All content is sourced directly from company filings and press releases, ensuring reliability for those monitoring developments in precision cancer immunotherapy.

Our news coverage focuses on three critical areas: Clinical Trial Advancements (Phase 1/2 updates, patient enrollment), Regulatory Progress (FDA communications, trial design approvals), and Strategic Collaborations (research partnerships, intellectual property developments). Each update is contextualized to show its significance within the broader oncology treatment landscape.

Bookmark this page for streamlined access to Context Therapeutics' latest developments in bispecific antibody research. Check back regularly for real-time updates on their mission to transform care for hormone-driven and treatment-resistant cancers.

Rhea-AI Summary
Context Therapeutics Inc. announced financial results for 2023, with cash reserves of $14.4 million. The company plans to file an IND for CTIM-76 by March 2024, targeting CLDN6-positive tumors. Recent highlights include amending collaboration terms with Integral Molecular, presenting promising preclinical data, and upcoming participation in the Needham Virtual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.96%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. (CNTX) announces Q3 2023 financial results, with $21.7 million in cash and cash equivalents. The company is on track to file an IND for CTIM-76 in late Q1 2024, supported by promising preclinical data presented at the SITC 38th Annual Meeting. CTIM-76 demonstrated broad therapeutic potential and differentiated product profile, positioning it as a strong candidate for addressing CLDN6-positive tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
-
Rhea-AI Summary
Context Therapeutics Inc. announces encouraging preclinical data for CTIM-76, a Claudin 6 x CD3 T-cell engaging bispecific antibody. CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models. Benchmarking studies show CTIM-76's differentiated product profile. CTIM-76 IND filing on track for late Q1 2024. Data to be presented at SITC 38th Annual Meeting on November 3rd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
Rhea-AI Summary
Context Therapeutics Inc. will present a poster on its preclinical asset, CTIM-76, at the SITC 38th Annual Meeting. The poster will discuss the development of CTIM-76, a highly specific Claudin 6 bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.22%
Tags
none
-
Rhea-AI Summary
Context Therapeutics Inc. announces financial results for Q2 2023 and provides updates on preclinical asset CTIM-76
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
-
Rhea-AI Summary

Context Therapeutics Inc. (NASDAQ:CNTX) is advancing therapies for solid tumors, focusing on Claudin 6 (CLDN6). The company is developing CTIM-76, a bispecific antibody targeting CLDN6, estimated to potentially treat 62,500 metastatic cancer patients in the U.S. CLDN6's unique presence in specific cancers, like ovarian and lung cancers, enables targeted T cell activation, minimizing damage to healthy cells. Context aims to address the limitations of current treatments, which can harm both cancerous and healthy cells, causing significant side effects. The company is set to present preclinical data at the AACR Annual Meeting on April 17 and plans to submit an IND filing by Q1 2024 for clinical trials. For more details, visit www.contexttherapeutics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary

Context Therapeutics Inc. (Nasdaq: CNTX) announced that CEO Martin Lehr will participate in two virtual investor conferences in April 2023. The details are: Diamond Equity Emerging Growth Invitational Investor Conference presentation on April 5 at 9:40 a.m. ET, and 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET, where one-on-one meetings will also occur. Context is focused on developing CTIM-76, a bispecific antibody targeting CLDN6-positive tumors, currently in preclinical development. For further information, visit contexttherapeutics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
conferences
Rhea-AI Summary

Context Therapeutics Inc. (Nasdaq: CNTX) announced a strategic shift prioritizing the development of CTIM-76, a Claudin 6 (CLDN6) bispecific antibody to treat solid tumors, while discontinuing the ONA-XR program. The company reported a net loss of $14.8 million for 2022, an increase from $10.5 million in 2021. Cash and equivalents at year-end were approximately $35.5 million, expected to fund operations into late 2024. The IND application for CTIM-76 is anticipated in Q1 2024. Preclinical data will be presented at the AACR Annual Meeting 2023. The decision to cease ONA-XR development was influenced by challenging market conditions and study findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
Context Therapeutics Inc

Nasdaq:CNTX

CNTX Rankings

CNTX Stock Data

75.63M
88.62M
2.78%
97.4%
3.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
PHILADELPHIA